Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC) - Concepedia

Concepedia

Publication | Open Access

Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC)

DOI Full Paper Access

21

Citations

14

References

2021

Year

Konstantinos Syrigos, Istvan Abert, Zoran Andric, Igor Bondarenko, Mikhail Dvorkin, Kristina Galić, Rinat Galiulin, Vladimer Kuchava, Virote Sriuranpong, Dmytro Trukhin,

References

	Year	Citations

Page 1